蒋
蒋元森 Directeur exécutif
Other
FR FR · AMF
Discover the detailed record of transactions filed by 蒋元森, Directeur exécutif. Officer active across 1 companies, notably 同和药业. Aggregated, 13 disclosures have been published. Regulator: AMF. The full history is free.
Declarations 13 total
Executives ● Purchase同 同和药业 21 SZSE 723,800 shares
SZSE:173000005346049100 · 9 Dec 2021
Ideal exit: 5 Sept 2022 (T+270) Executives ● Purchase同 同和药业 21 SZSE 341,900 shares
SZSE:173000005150958140 · 8 Dec 2021
Ideal exit: 4 Sept 2022 (T+270) Executives ● Purchase同 同和药业 21 SZSE 87,600 shares
SZSE:173000005146928030 · 7 Dec 2021
Ideal exit: 3 Sept 2022 (T+270) Executives ● Purchase同 同和药业 21 SZSE 118,000 shares
SZSE:173000005146847070 · 7 Dec 2021
Ideal exit: 3 Sept 2022 (T+270) Executives ● Purchase同 同和药业 36 SZSE 240,320 shares
SZSE:173000005142443650 · 6 Dec 2021
Ideal exit: 2 Sept 2022 (T+270) Executives ● Purchase同 同和药业 21 SZSE 360,000 shares
SZSE:173000005130234340 · 2 Dec 2021
Ideal exit: 29 Aug 2022 (T+270) Executives ● Purchase同 同和药业 18 SZSE 39,500 shares
SZSE:173000005038892640 · 3 Nov 2021
Ideal exit: 31 Jul 2022 (T+270) Executives ● Purchase同 同和药业 7 SZSE 423,600 shares
SZSE:173000005129698200 · 24 Sept 2021
Ideal exit: 21 Jun 2022 (T+270) Executives ● Purchase同 同和药业 7 SZSE 50,000 shares
SZSE:173000004905057730 · 23 Sept 2021
Ideal exit: 20 Jun 2022 (T+270) Executives ● Purchase同 同和药业 7 SZSE 300,000 shares
SZSE:173000004818779360 · 10 Sept 2021
Ideal exit: 7 Jun 2022 (T+270) Executives ● Purchase同 同和药业 7 SZSE 200,000 shares
SZSE:173000004799263680 · 9 Sept 2021
Ideal exit: 6 Jun 2022 (T+270) Executives ● Purchase同 同和药业 7 SZSE 300,000 shares
SZSE:173000004441833100 · 26 May 2021
Ideal exit: 20 Feb 2022 (T+270) Executives ● Purchase同 同和药业 7 SZSE 949,400 shares
SZSE:173000004436315800 · 24 May 2021
Ideal exit: 18 Feb 2022 (T+270) About 蒋元森 Jiang Yuansen is an executive director at 同和药业, where he plays a key role in managing operations and corporate strategy. With significant experience in the pharmaceutical sector, he is responsible for innovation and the continuous improvement of the company's services.